Evidence map›Paper›PMID 28588089›Full record

ArticleJournal of the American Heart Association2017

Role of Circulating Fibroblast Growth Factor 21 Measurement in Primary Prevention of Coronary Heart Disease Among Chinese Patients With Type 2 Diabetes Mellitus.

Chi Ho Lee, Yu Cho Woo, Wing Sun Chow, Chloe Yu Yan Cheung, Carol Ho Yi Fong, Michele Mae Ann Yuen, Aimin Xu, Hung Fat Tse, Karen Siu Ling Lam

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Heart Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Hepatic FGF21: Its Emerging Role in Inter-Organ Crosstalk and Cancers.International journal of biological sciences · 2022
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. The roles of FGF21 in atherosclerosis pathogenesis.Reviews in endocrine & metabolic disorders · 2019
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Chi Ho LeeDepartment of Medicine, The University of Hong Kong, China.
Yu Cho WooDepartment of Medicine, The University of Hong Kong, China.
Wing Sun ChowDepartment of Medicine, The University of Hong Kong, China.
Chloe Yu Yan CheungDepartment of Medicine, The University of Hong Kong, China.
Carol Ho Yi FongDepartment of Medicine, The University of Hong Kong, China.
Michele Mae Ann YuenDepartment of Medicine, The University of Hong Kong, China.
Aimin XuDepartment of Medicine, The University of Hong Kong, China.
Hung Fat TseDepartment of Medicine, The University of Hong Kong, China hftse@hku.hk ksllam@hku.hk.
Karen Siu Ling LamDepartment of Medicine, The University of Hong Kong, China hftse@hku.hk ksllam@hku.hk.
University of Hong Kong · HKChinese University of Hong Kong · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFibroblast growth factor 21 (FGF21) has demonstrated beneficial effects on lipid and carbohydrate metabolism. In cross-sectional studies, an association of raised circulating FGF21 levels with coronary heart disease (CHD) was found in some but not all studies. Here we investigated prospectively whether baseline serum FGF21 levels could predict incident CHD in subjects with type 2 diabetes mellitus and no known cardiovascular diseases. METHODS AND

resultsBaseline serum FGF21 levels were measured in 3528 Chinese subjects with type 2 diabetes mellitus recruited from the Hong Kong West Diabetes Registry. The role of baseline serum FGF21 levels in predicting incident CHD over a median follow-up of 3.8 years was analyzed using Cox regression analysis. Among 3528 recruited subjects without known cardiovascular diseases, 147 (4.2%) developed CHD over a mean follow-up of 4 years. Baseline serum log-transformed FGF21 levels were significantly higher in those who had incident CHD than those who did not (222.7 pg/mL [92.8-438.4] versus 151.1 pg/mL [75.6-274.6];

conclusionsWe have demonstrated, for the first time, that serum FGF21 level is an independent predictor of incident CHD and might be usefully utilized as a biomarker for identifying type 2 diabetes mellitus subjects with raised CHD risk, for primary prevention.

Indexed as

Asian PeoplePrimary PreventionAgedBiomarkersChi-Square DistributionCoronary DiseaseDiabetes Mellitus, Type 2FemaleFibroblast Growth FactorsHong KongHumansIncidenceKaplan-Meier EstimateLinear ModelsMaleMiddle AgedBiomarkersfibroblast growth factor 21Fibroblast Growth Factorsadipokinecardiovascular diseasecoronary heart diseaseprimary preventiontype 2 diabetes mellitus

Identifiers

PMID28588089
PMCPMC5669163
OpenAlexW2622420309

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.